Approval · Notice of Compliance 25235 · 2021
ABILIFY: Notice of Compliance 25235
Issued February 12, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25235
- Date
- February 12, 2021
- Company
- Otsuka Pharmaceutical Co LtdChiyoda-Ku Tokyo, --, Japan
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Sagety updates and to transition the product monograph format in alignment with the 2016 product monograph guidance document
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ABILIFY | Not yet assigned | — |
Medicinal ingredients
- ARIPIPRAZOLE 2 MG per TAB
- ARIPIPRAZOLE 5 MG per TAB
- ARIPIPRAZOLE 10 MG per TAB
- ARIPIPRAZOLE 15 MG per TAB
- ARIPIPRAZOLE 20 MG per TAB
- ARIPIPRAZOLE 30 MG per TAB